On Tuesday, Curis, Inc. announced that the FDA has allowed patient enrollment to resume in the monotherapy phase of its TakeAim Leukemia Phase I/II trial studying emavusertib.
Featured Posts
Dutch medical device maker Philips said on Monday it has expanded an earlier recall of some respiratory machines to a total of 1,700 devices globally due to possible contamination of a plastic component with a non-compatible material.
The United Nations-backed COVAX vaccine program will send 10 million doses of Pfizer/BioNTech COVID-19 shots for children to Mexico by the end of September, a senior Mexican official announced Tuesday.
Outlook Therapeutics, Inc., a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced it has re-submitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ONS-5010, an investigational ophthalmic therapy which, if approved, will be branded as LYTENAVA™ (bevacizumab-vikg) for the treatment of wet age-related macular degeneration (wet AMD).
It is possible to eliminate the monkeypox outbreak in Europe, World Health Organization officials said on Tuesday, highlighting evidence that case counts are slowing in a handful of countries.
U.S. Supreme Court Justice Sonia Sotomayor on Monday declined to block New York City from enforcing its mandate that all municipal workers be vaccinated against COVID-19, rebuffing a police detective who challenged the public health policy.
Starting next week, Americans will not be able to order free at-home COVID tests from a website set up by the U.S. government due to limited supply.
On Monday, Bayer revealed data from a Phase III trial of Kerendia (finerenone), showing the drug’s potential to reduce the risk of all-cause and cardiovascular mortality in type 2
Over the past decade, the clinical research industry has steadily adopted new digital technologies to streamline business processes and improve user experiences, realizing efficiencies and insights along the way.
The U.S. government said on Monday it would provide about $11 million to support the packaging of Bavarian Nordic’s Jynneos monkeypox vaccine at a U.S.-based manufacturer’s facility.